Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Stopped early · Phase 2
Conditions studied: Breast Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine together with imatinib mesylate may kill more tumor cells. PURPOSE: This randomized phase II trial is studying gemcitabine and imatinib mesylate to see how well they work compared to gemcitabine alone in treating patients with previously treated locally advanced or metastatic breast cancer.
Key facts
- Study ID
- NCT00323063
- Run by
- Rutgers, The State University of New Jersey
- People needed
- 49
- Starts
- 2006-05-01
- Expected to finish
- 2016-06-20
- Last updated by the study team
- 2023-03-29
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
- University of Maryland Greenebaum Cancer Center — Baltimore, Maryland, United States
- Cooper Hospital/University Medical Center — Camden, New Jersey, United States
- Rutgers Cancer Institute of New Jersey at Hamilton — Hamilton, New Jersey, United States
- Mountainside Hospital — Montclair, New Jersey, United States
- Jersey Shore Cancer Center at Jersey Shore University Medical Center — Neptune City, New Jersey, United States
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
- Saint Peter's University Hospital — New Brunswick, New Jersey, United States
- NJ Medical School — Newark, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.